ArticleMalaria journal2025
Fighting malaria in Shangla District, Pakistan: insight into epidemiology, risk factors, and strategic control measures (2020-2024).
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a significant public health challenge in District Shangla, Pakistan, exacerbated by ecological diversity, seasonal transmission, and limited health infrastructure. This 5-year epidemiological study aimed to assess malaria trends, species distribution, risk factors, and intervention outcomes from 2020 to 2024.
methodsA retrospective analysis was performed on 130,401 laboratory-confirmed malaria cases identified from 572,696 febrile individuals screened between 2020 and 2024. Data were collected through district health surveillance systems and field-based reports. Epidemiological indicators, including Annual Parasite Incidence (API), Test Positivity Rate (TPR), and Annual Blood Examination Rate (ABER), were analyzed alongside demographic, diagnostic, seasonal, and behavioral data. The impacts of interventions were assessed by comparing trends before and after the interventions.
resultsMalaria incidence increased sharply from 2020 to 2023, with API rising from 2 to 61 per 1000 populations, TPR from 3 to 32%, and ABER from 5 to 19%. In 2024, these indicators declined (API: 46/1000; TPR: 27%; ABER: 18%) following targeted interventions. Plasmodium vivax comprised 95% of cases, followed by Plasmodium falciparum (4.6%) and mixed infections (0.4%). Only 18% of cases were microscopy-confirmed; the remainder relied on rapid diagnostic tests (RDTs). Adults ≥ 15 years accounted for 67% of cases, with a male predominance (54%). Seasonal peaks varied: P. vivax peaked in July-August, while P. falciparum peaked in October-November. Risk factors included poor treatment adherence (only 14% completed primaquine regimens), absence of G6PD screening, misinformation, reliance on informal providers, and population mobility. DISCUSSION: The rise in malaria burden reflects climate-sensitive transmission, diagnostic gaps, and inadequate treatment adherence. The decline in 2024 corresponds to coordinated responses, including deploying 78 diagnostic and treatment centers, expanded IRS, LLIN distribution, and health education campaigns. However, persistent gaps in vector surveillance, diagnostic accuracy, primaquine adherence, and health worker training hinder progress.
conclusionMalaria control in Shangla requires an integrated, climate-adaptive elimination strategy. Priorities include enhanced vector control, improved diagnostic access, universal G6PD testing, community-based health education, and use of short-course antimalarial regimens with full primaquine adherence to sustain control and advance toward elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.